Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases. Issue 5 (May 2022)

• Record Type: Journal Article
• Authors: Mishra, Neeraj; Ashique, Sumel; Garg, Ashish; Rai, Vineet Kumar; Dua, Kamal; Goyal, Amit; Bhatt, Shvetank
• Is Part Of: Drug discovery today. Volume 27:Issue 5(2022)
• Page Start: 1431
• Page End: 1440
• Publication Date: 2022-05
• Subjects: Neurodegenerative disorders -- Small interfering RNA -- Nanoparticles -- Nanostructured lipid carriers -- Solid lipid nanoparticle -- Liposomes; Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2022.01.003
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: The clinical application of siRNA for brain disease therapy remains a big challenge. The siRNA based gene silencing technology has proven potential for treatment of NDs. Nanocarriers can provide promising opportunities for improving NDs. We highlighted the role of nanocarriers for the treatment of NDs. Abstract: Neurodegenerative disorders (NDs) lead to the progressive degeneration of the structural and physiological functions of the central and peripheral nervous systems, resulting in lifelong cognitive and motor dysfunction. Although comprehensive treatment of NDs is lacking, small interfering (si)RNA has shown therapeutic utility in the form of cellular nuclease-driven downregulation of mRNA levels. Various nanotechnologies have been used to modulate crucial physicochemical and biopharmaceutical properties of siRNA to provide protection and to enhance biomembrane interactions, residence times, tissue absorption, and cellular internalization for improved cytoplasm and/or nucleus interactions. In this review, we highlight advances in, and the role of, siRNA-based nanocarriers for the treatment of various NDs.